Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Review, H1 2016

  • ID: 3734782
  • Drug Pipelines
  • 50 pages
  • Global Markets Direct
1 of 4
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Review, H1 2016

Summary

‘Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Review, H1 2016’, provides in depth analysis on Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted pipeline therapeutics.

The report provides comprehensive information on the Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1)
- The report reviews Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Introduction

Report Coverage

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) Overview

Therapeutics Development

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Products under Development by Stage of Development

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Products under Development by Therapy Area

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Products under Development by Indication

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Products under Development by Companies

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Products under Development by Universities/Institutes

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Companies Involved in Therapeutics Development

Amgen Inc.

Advinus Therapeutics Ltd.

Astellas Pharma Inc.

Caldan Therapeutics Limited

Connexios Life Sciences Pvt. Ltd.

Daiichi Sankyo Company, Limited

Hyundai Pharmaceutical Co., Ltd.

Japan Tobacco Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Drug Profiles

AM-1638 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-3189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-6226 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-2034178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-2575959 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNX-011-67 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-1558 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HD-6277 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTT-851 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 and GPR120 Receptors for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GPR40 for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR40 for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TUG-770 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Dormant Projects

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Discontinued Products

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Featured News & Press Releases

Apr 10, 2012: Connexios in discussions to partner early-stage GPR40 diabetes drug, CRO will be chosen in US/EU -CEO

Jun 27, 2011: Connexios Life Science Presents Preclinical Data On CNX-011-67 At American Diabetes Association Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by Advinus Therapeutics Ltd., H1 2016

Pipeline by Astellas Pharma Inc., H1 2016

Pipeline by Caldan Therapeutics Limited, H1 2016

Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016

Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016

Pipeline by Japan Tobacco Inc., H1 2016

Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll